Study Builds on the Extensive Clinical Evidence for Steroid Releasing Sinus Implants MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ: XENT) today announced a pivotal study publication of the second cohort of the prospective, randomized, blinded, multi-center

Novel navigation technology and recently FDA-cleared sinuplasty balloon expand Intersect ENT’s commercial product portfolio Extends Intersect ENT’s footprint in U.S. and European ENT physicians’ offices MENLO PARK, Calif. and BERLIN --(BUSINESS WIRE)--Sep. 15, 2020-- Intersect ENT, Inc.

Mark L. Alley to serve as Vice President of Sales MENLO PARK, Calif. --(BUSINESS WIRE)--May 4, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L.

MENLO PARK, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the resignations of Rick Anderson, PTV Healthcare Capital, and Mark Fletcher, Medtronic,